Response to: 'Comment on 'Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis' by Kuwabara et al' by Rios Rodriguez et al

We thank Rios Rodriguez et al for sharing their interesting case with us. Both of us reported that tofacitinib, a janus kinase (JAK) inhibitor, showed a favourable therapeutic effect in each patient with Takayasu arteritis (TAK) complicated by ulcerative colitis1 or psoriatic arthritis.2 These complications are in the same spectrum as spondyloarthritis, in which IL-23/Th17 axis plays an important pathophysiological role and the effectiveness of JAK inhibitors was …